May 2018 Vol 9, No 5

The Biden Cancer Initiative builds on former Vice President Joe Biden’s work on the National Cancer Moonshot Initiative by developing and driving implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research, and care, and to reduce disparities in cancer outcomes.
The authors present their findings from a study testing the effects of an early intervention by the Breast Cancer Navigator on distress.
JONS Editor in Chief, Lillie Shockney, RN, BS, MAS, ONN-CG, offers her insights on the timely topic of commercially available genetic testing.
The National Comprehensive Cancer Network has overhauled its guidelines for the management of colon and rectal cancers.
The updated guidelines from the National Comprehensive Cancer Network on the management of breast expand treatment options in HER2-positive disease to include extended adjuvant neratinib after completion of trastuzumab in patients with high risk of recurrence and recognize a third CDK 4/6 inhibitor in hormone-sensitive breast cancer.
The updated guidelines from the National Comprehensive Cancer Network on the management of metastatic non–small cell lung cancer reflect the addition of osimertinib as a first-line option in patients with an epidermal growth factor receptor (EGFR)-sensitizing mutation and as subsequent therapy in patients whose disease progresses following another tyrosine kinase inhibitor if they develop a T790M resistance mutation.
Recently Sellas Life Sciences Group announced data from a study of NeuVax (nelipepimut-S) in combination with Herceptin (trastuzumab) in patients with HER2 1+/2+ breast cancer.
Participating in a national conversation on improving cancer care is a great honor. We are being asked to reconsider how we address cancer from prevention through survivorship. It’s a huge undertaking, but a very exciting one. I’m delighted to be a part of it.” - Danelle Johnston, MSN, RN, ONN-CG, OCN
Federal health officials this week allowed a genetic testing firm to sell kits to consumers to test whether they carry gene mutations that put them at higher risk for breast and ovarian cancer.

Results 1 - 9 of 9

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code